Document is current
Any future updates will be listed below
-
Authors
Moradi, Najmeh https://orcid.org/0000-0001-8500-1931
O’Connor, Nicole https://orcid.org/0000-0002-6654-7178
Thomson, Katie H. https://orcid.org/0000-0002-9614-728X
Shabaninejad, Hosein https://orcid.org/0000-0001-9512-1398
Sotire, Tumi https://orcid.org/0000-0002-5330-9568
Still, Madeleine https://orcid.org/0000-0003-0625-6325
Fernandez-Garcia, Cristina https://orcid.org/0000-0002-7113-225X
Wallace, Sheila A. https://orcid.org/0000-0003-2853-3653
Williams, Oleta https://orcid.org/0009-0000-2126-7546
Vale, Luke https://orcid.org/0000-0001-8574-8429
Sagoo, Gurdeep S. https://orcid.org/0000-0003-1427-1437
-
Funding
Funding for this research was provided by:
Evidence Synthesis Programme (NIHR135721)
- License Information
-
More Information
Article History
Accepted: 27 May 2024
First Online: 11 June 2024
Declarations
: This article has not been externally peer reviewed by <i>PharmacoEconomics</i>.
: Najmeh Moradi, Nicole O’Connor, Katie Thomson, Hosein Shabaninejad, Tumi Sotire, Madeleine Still, Cristina Fernandez-Garcia, Sheila Wallace, Oleta Williams, Luke Vale, and Gurdeep S. Sagoo have no conflicts of interest to declare.
: The independent EAG report was commissioned by the NIHR Evidence Synthesis Programme as project number NIHR135721. See the Health Technology Assessment (HTA) programme website for further project information () This summary of the EAG report was compiled after NICE issued the Final Appraisal Determination. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NICE or the Department of Health.
: All authors contributed to the study conception and design and were involved with the work of the EAG. The manuscript was initially drafted by N.M. and N.O. All authors were involved in the critical review of the clinical and cost-effectiveness evidence, drafting of the EAG report, and providing critical feedback on the manuscript. All authors approved the final version.
